Founded by cardiac physicians and scientists, i-Cordis develops immunomodulatory medicines for heart failure with preserved ejection fraction and related cardiovascular diseases. The company is advancing a PEGylated version of pirfenidone, drawing on findings from the Phase II PIROUETTE trial to address the drug’s dosing, tolerability, and pharmacokinetic limitations. Its team combines cardiac immunology with medicinal chemistry and pharmaceutical drug-development experience, and the company has received funding through the NHLBI SBIR Program.
NHLBI SBIR Program Funding
Compliance program
VasocureVasocure is a novel therapeutics company developing peptide medicines for vascular disease, centered on Pedifin, its patented F11R blocker for neointimal disease and atherosclerosis. Founded by nephrologists and scientists involved in discovering the human F11 receptor, the company draws on more than two decades of research into vascular access failure in dialysis patients. Its 62-candidate pipeline spans nephrology, cardiology, and oncology, with Pedifin in preclinical and first-in-human studies.NEW YORK, NY
CorvidaneCorvidane is a privately held life sciences company developing patented therapeutic programmes for complex cardiometabolic diseases, including atherosclerosis and MASH. Co-founded by Damion J. Boyer and chemical engineer John M. Burke, the company takes a biology-driven approach aimed at addressing interconnected lipid, inflammatory, and fibrotic disease processes rather than a single target. Its lead programme, CVMB-216, is being advanced through structured preclinical development toward regulated clinical pathways and potential partnerships.NETHERLANDS &, NY
PECA LabsFounded by Carnegie Mellon alumni, including a pediatric surgeon, PECA Labs develops cardiovascular implantable devices built around a polymer platform and novel designs. The Pittsburgh company makes vascular grafts and heart-valve devices, including the radiopaque exGraft and investigational MASA Valve, whose first-in-human pediatric implant was completed in 2023. PECA Labs is ISO 13485:2016 certified.PITTSBURGH, PA
HighTide Therapeutics, IncFounded in 2011 by scientist and entrepreneur Liping Liu, HighTide Therapeutics is a biopharmaceutical company developing multifunctional, multi-targeted therapies for cardiovascular-kidney-metabolic diseases. Its lead candidate, HTD1801, is an oral metabolic modulator built from berberine and ursodeoxycholic acid and is being evaluated in global clinical programs. HighTide also maintains an early-stage research portfolio spanning acute inflammatory disease, weight modulation and neurodegenerative conditions.ROCKVILLE, MD